Steps towards standard medical treatment of rheumatoid arthritis: A practical guide
Abstract
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, involving the longterm use of drugs that act by different mechanisms to treat this disease in an effective way. Current eligibility criteria enable early diagnosis of RA, which should result in early treatment. An important component of therapy is good cooperation with a patient, who has an impact on modifiable factors that affect the course of RA and the efficacy of treatment, such as treatment of periodontal infections, weight reduction and smoking cessation. RA treatment should follow the treat-to-target (T2T) strategy, according to which patients should be continuously monitored for treatment efficacy and therapy should be adjusted to achieve improvement after 3 months and disease remission after 6 months. There is an increasing number of drugs available that allow a more precise choice of therapy, however, there is still little availability of drugs reimbursed under the B.33 Drug Program.
During the course of therapy, it is also necessary to monitor the safety of the treatment used.
Keywords: rheumatoid arthritismodifiable RA risk factorsmethotrexateT2T strategyconventional disease-modifying drugsdisease remission
References
- Batko B, Stajszczyk M, Świerkot J, et al. Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Arch Med Sci. 2019; 15(1): 134–140.
- Tanaka Y. Rheumatoid arthritis. Inflamm Regen. 2020; 40: 20.
- Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569–2581.
- van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020; 110: 102392.
- Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76(6): 948–959.
- Saevarsdottir S, Rezaei H, Geborek P, et al. SWEFOT study group. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2015; 74(8): 1509–1514.
- Cosgarea R, Tristiu R, Dumitru RB, et al. Effects of non-surgical periodontal therapy on periodontal laboratory and clinical data as well as on disease activity in patients with rheumatoid arthritis. Clin Oral Investig. 2019; 23(1): 141–151.
- George MD, Giles JT, Katz PP, et al. Impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017; 69(12): 1789–1798.
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6): 685–699.
- Sun KJ, Liu LL, Hu JH, et al. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis. Medicine (Baltimore). 2021; 100(7): e24579.
- Baghdadi LR. Correction: Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One. 2020; 15(12): e0243960.
- Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021; 57(2): 2000337.
- Chester Wasko M, Dasgupta A, Ilse Sears G, et al. Prednisone use and risk of mortality in patients with rheumatoid arthritis: moderation by use of disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2016; 68(5): 706–710.
- Poór G, Strand V. Leflunomide Multinational Study Group. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (Oxford). 2004; 43(6): 744–749.
- Fajardo-Robledo NS, Jacobo-Cuevas H, Perez-Guerrero EE, et al. Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels. Sci Rep. 2022; 12(1): 1877.
- CHPL Adalimumab (Hyrimoz). https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_pl.pdf.
- Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79(1): 39–52.
